U.S. Healthcare Services Stock News

NYSE:LDOS
NYSE:LDOSProfessional Services

Leidos Hypersonics Win Expands Role In High Priority Defense Programs

Leidos Holdings (NYSE:LDOS) has been awarded a U.S. Army contract worth up to $2.7b to move hypersonic weapons programs toward production. The award consolidates several advanced hypersonic efforts under a single umbrella, aimed at accelerating development and deployment. The contract supports the company’s NorthStar 2030 vision by expanding its role in high-priority national defense work. For investors watching Leidos at a share price of $124.17, this hypersonics award arrives after a...
NYSE:KVYO
NYSE:KVYOSoftware

Klaviyo Claude Integration Shifts AI To Execution As Shares Screen Undervalued

Klaviyo (NYSE:KVYO) has launched a deeper integration with Anthropic's Claude through a new Model Context Protocol connector. The update allows marketers to use natural language inside Claude to pull Klaviyo first party data, generate campaigns, and automate multi step workflows. This moves Klaviyo's AI tools from insight generation into direct execution across reporting and campaign creation. Klaviyo is rolling out this Claude integration at a time when the stock is trading at $14.24 and...
NYSE:AON
NYSE:AONInsurance

Has Aon (AON) Share Weakness Opened A Valuation Opportunity For Investors

Wondering whether Aon’s current share price still reflects good value, or if most of the opportunity has already been priced in? This article looks at the stock through a clear valuation lens so you can frame your own view. Aon’s share price closed at US$310.90, with returns of 0.9% over the past week, a decline of 4.5% over the past month, a decline of 9.7% year to date and a decline of 10.9% over the past year. These figures may change how investors think about its risk and return trade...
NasdaqGM:LGND
NasdaqGM:LGNDPharmaceuticals

A Look At Ligand Pharmaceuticals (LGND) Valuation After XOMA Deal And Viking TR Beta Licensing Dispute

Ligand Pharmaceuticals (LGND) is back in focus after its latest quarterly update, which combined higher royalty revenues and adjusted EPS with the planned XOMA acquisition and a contested termination of the Viking TR Beta licensing program. See our latest analysis for Ligand Pharmaceuticals. The stock has eased in the very short term, with a 7 day share price return of down 4.9%. However, the 90 day share price return of 21.8% and the 1 year total shareholder return of 110.5% point to strong...